Abstract 30P
Background
Accelerated partial breast irradiation (APBI) is now widely adopted in the treatment with low risk early breast cancer worldwide. Both stereotactic body radiotherapy (SBRT) using Cyberknife (CK) and interstitial brachytherapy (IB) are available for APBI. This study was designed to compare the dosimetric characteristics of organ at risk and the clinical outcome between two different techniques.
Methods
Forty-four patients with left sided early breast cancer treated by APBI in our institute were reviewed. The radiation doses are 30Gy in 5 fractions, in 5 consecutive days using CK and 34Gy in 10 fractions, BID in 5 consecutive days using IB. Dosimetric parameters of OARs were calculated for both techniques and compared. The preliminary clinical outcomes include the local recurrence rate, acute toxicity (CTCAE V5.0) and cosmetic evaluation (Harvard scales) were analyzed.
Results
The median follow up time of CK group and IB group were 19.3 months (range: 4.5∼48.4 months) and 53.5months, respectively. Two patients from IB group had sentinel lymph node micrometastasis in the final pathology report and whole breast irradiation plus regional lymph node irradiation was added subsequently. One patient from IB group had regional lymph node recurrence during follow up and underwent surgery and re-irradiation with stable disease now. Most common acute toxicity was grade 1 radiation dermatitis. Neither radiation pneumonitis nor heart events were noted during the follow up. Multiple small scars left for more than 6 months in a few patients after interstitial brachytherapy. Patients reported cosmetic results according to Harvard scales, with “good” score in most patient of IB group and no cases described as “poor”. Dosimetric parameters of OAR showed the heartV150cGy of CK and IB was 23.5% and 59.2%. The mean heart dose of CK and IB were 117.1cGy and 215.6cGy.
Conclusions
APBI by SBRT using CK is a non-invasive procedure and has better dose-sparing effect on the heart. There were less risks of wound infection or delayed wound healing when using CK. Since no small scars left on the breast when using CK, better cosmetic outcome is expected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract